Revolutionary non-invasive sonophoretic drug delivery technology

MuPharma's ultrasound based technologies enables a desired drug or vaccine to be non-invasively delivered to a controlled and precise depth within a desired target tissue layer.

Our novel devices permit drugs and vaccines to be delivered through tissue without the need for reformulation or penetration enhancers / adjuvants.

​Opportunities include:

  • targeted or systemic non-invasive drug / vaccine delivery applications; and

  • through mucosal delivery directly into the bloodstream, new commercial pathways for ingestible drugs that have failed in clinical trials or on-market, due their gastro-intestinal side effects or because of metabolic degradation in the liver.


Re-usable hand held actuator powers and monitors disposable tips that are directly applied to tissue.

Sterile, single use, disposable tips.



Elimination of intra-ocular injections and corneal tissue trauma

MuPharma's novel ocular device can deliver drugs to the front or back of the eye. 

Opportunities include:

  • non-invasive delivery of biologics (including monoclonal antibody drugs and other proteins) to the retina particularly for the treatment of (wet and potentially dry) Macular Degeneration and Diabetic Macular Edema;

  • non-invasive delivery of any chemically synthesised drug to anterior / posterior segments; and

  • non-invasive delivery of Riboflavin to the cornea for Collagen Cross-Linking to treat Keratoconus.



Creation of strong mucosal immunity - elimination of injections for vaccine delivery  

MuPharma's novel vaccine device can deliver vaccines to any mucosal surface of the body including the mouth,nose, lung, bowel and vagina. 

Opportunities include:

  • the creation of strong mucosal immunity for diseases that enter the body via mucous membranes including Covid-19, Influenza, Chlamydia, HIV, Tuberculosis as well as a host of other communicable diseases;

  • the potential for novel allergy treatments including for diseases like asthma; and

  • the potential for creating targeted vaccines to treat cancers that originate in epithelial tissue.



Graeme Samuel AC


Dr. Harry  Unger


Medical Director

Mark Unger


Managing Director

mupharma MuPharma MUPHARMA


mupharma MuPharma MUPHARMA
mupharma MuPharma MUPHARMA